GU Cancers Symposium 2013 - ARN-509 in men with high-risk non-metastatic castration-resistant prostate cancer, by Matthew R. Smith, MD, PhD, et al. - Slide Presentation

ORLANDO, FL, USA (UroToday.com) - Presented by Matthew R. Smith,¹ Emmanuel S. Antonarakis,² Charles J. Ryan,³ William R. Berry,⁴ Neal Shore,⁵ Glenn Liu,⁶ Joshi J. Alumkal,⁷ Celestia S. Higano,⁸ Edna Chow Maneval,⁹ and Dana E. Rathkopf¹⁰ at the 2013 Genitourinary Cancers Symposium - February 14 - 16, 2013 - Rosen Shingle Creek - Orlando, Florida USA

¹Massachusetts General Hospital and the Harvard Medical School, Boston, MA; ²Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD; ³UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; ⁴Cancer Centers of North Carolina, Raleigh, NC; ⁵Carolina Urologic Research Center, Myrtle Beach, SC; ⁶University of Wisconsin Carbone Cancer Center, Madison, WI; ⁷Oregon Health & Science University Knight Cancer Institute, Portland, OR; ⁸Seattle Cancer Care Alliance and the University of Washington, Seattle, WA; ⁹Aragon Pharmaceuticals, San Diego, CA; ¹⁰Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, NY

Read session highlights by a UroToday.com reporter.

View Full 2013 GU Cancers Symposium Coverage